Skip to main content
SpringerLink
Log in

Cefepime/Enmetazobactam: First Approval

  • ADISINSIGHT REPORT
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cephalosporin and an extended-spectrum β-lactamase (ESBL) inhibitor, is being developed by Allecra Therapeutics and ADVANZ PHARMA for the treatment of infections caused by multi-drug-resistant (MDR) Gram-negative bacteria. In February 2024, cefepime/enmetazobactam was approved in the USA for use in adults with complicated urinary tract infections (cUTI) including pyelonephritis, caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex. In March 2024, cefepime/enmetazobactam was approved in the EU for use in adults for the treatment of cUTI, including pyelonephritis, and hospital-acquired pneumonia, including ventilator associated pneumonia, and the treatment of patients with bacteraemia occurring in association with or suspected to be associated with any of these infections. This article summarizes the milestones in the development of cefepime/enmetazobactam leading to this first approval for the treatment of adults with infections caused by MDR Gram-negative bacteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Papp-Wallace KM, Bethel CR, Caillon J, et al. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent β-lactam-β-lactamase inhibitor combination. Antimicrob Agents Chemother. 2019;63(5):e00105-e119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Belley A, Morrissey I, Hawser S, et al. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam. J Glob Antimicrob Resist. 2021;25:93–101.

    Article  CAS  PubMed  Google Scholar 

  3. Kaye KS, Belley A, Barth P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328(13):1304–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother. 2021;76(3):550–60.

    Article  CAS  PubMed  Google Scholar 

  5. Magill SS, O’Leary E, Ray SM, et al. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clin Infect Dis. 2021;72(10):1784–92.

    Article  CAS  PubMed  Google Scholar 

  6. Advani SD, Claeys K. Cefepime/enmetazobactam for complicated urinary tract infections. JAMA. 2022;328(13):1299–301.

    Article  PubMed  Google Scholar 

  7. Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, et al. Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother. 2022;66(2): e0167621.

    Article  PubMed  Google Scholar 

  8. European Medicines Agency. Cefepime/enmetazobactam: EU prescribing information. 2024. https://www.ema.europa.eu/. Accessed 11 Apr 2024.

  9. Allecra Therapeutics. Cefepime/enmetazobactam: US prescribing information. 2024. https://www.fda.gov/. Accessed 26 Feb 2024.

  10. Allecra Therapeutics. Allecra Therapeutics announces US FDA approval for EXBLIFEP® for the treatment of complicated urinary tract infections [media release]. 27 Feb 2024. https://www.allecra.com. Accessed 27 Feb 2024.

  11. US Food & Drug Administration. Exblifep (cefepime and enmetazobactam): approval letter. 2024. https://www.fda.gov/. Accessed 20 Mar 2024.

  12. ADVANZ PHARMA Limited, Allecra Therapeutics. ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP® (cefepime/enmetazobactam) for the treatment of severe infections [media release]. 27 Mar 2024. https://www.advanzpharma.com/. Accessed 27 Mar 2024.

  13. European Medicines Agency. Cefepime/enmetazobactam: EU assessment report. 2024. https://www.ema.europa.eu/. Accessed 11 Apr 2024.

  14. Allecra Therapeutics. Allecra Therapeutics and ADVANZ PHARMA sign exclusive license and supply agreement for Allecra’s antibiotic cefepime/enmetazobactam in Europe [media release]. 13 Jan 2022. https://www.allecra.com. Accessed 13 Jan 2022.

  15. Allecra Therapeutics GmbH, Shanghai Haini Pharmaceutical Co Ltd. Allecra Therapeutics and Shanghai Haini Pharmaceutical announce exclusive licensing agreement for cefepime/enmetazobactam for Greater China [media release]. 21 Dec 2020. https://www.allecra.com. Accessed 21 Dec 2020.

  16. Orchid Chemicals & Pharmaceuticals. Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics [media release]. 18 Apr 2013. https://www.orchidpharma.com. Accessed 18 Apr 2013.

  17. Principe L, Lupia T, Andriani L, et al. Microbiological, clinical, and PK/PD features of the new anti-Gram-negative antibiotics: β-lactam/β-lactamase inhibitors in combination and cefiderocol—an all-inclusive guide for clinicians. Pharmaceuticals (Basel). 2022;15:463.

    Article  CAS  PubMed  Google Scholar 

  18. Morrissey I, Magnet S, Hawser S, et al. In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from US and European hospitals during 2014–2015. Antimicrob Agents Chemother. 2019;63(7):e00514-e519.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tselepis L, Langley GW, Aboklaish AF, et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2020;56(1): 105925.

    Article  CAS  PubMed  Google Scholar 

  20. Hawser S, Morrissey I, Kothari N, et al. Influence of genotype on the activity of cefepime/enmetazobactam against beta-lactam resistant Enterobacterales collected from Europe in 2019-2021 [abstract and poster no. P0097]. In: 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 2023.

  21. Knechtle P, Shapiro S, Morrissey I, et al. Sigmoid Emax modeling to define the fixed concentration of enmetazobactam for MIC testing in combination with cefepime. Antimicrob Agents Chemother. 2021;65(8): e0092621.

    Article  PubMed  Google Scholar 

  22. Belley A, Kothari N, Monti F, et al. Antibacterial activity of cefepime/enmetazobactam and comparator agents against US enterobacterales clinical isolates collected from 2019–2021. Open Forum Infect Dis. 2023;10(Suppl 2):S60–70.

    Google Scholar 

  23. Hawser S, Morrissey I, Kothari N, et al. Surveillance of cefepime/enmetazobactam against European isolates of Enterobacterales collected between 2019 and 2021, including cephalosporin-resistant phenotypes [Abstract and poster no. P0289]. In: 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 2023.

  24. Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015;59(5):2688–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bernhard F, Odedra R, Sordello S, et al. Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2020;64(6):e00078-e120.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Johnson A, McEntee L, Farrington N, et al. Pharmacodynamics of cefepime combined with the novel extended-spectrum-β-lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(6):e00180-e220.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Das S, Fitzgerald R, Ullah A, et al. Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: towards new treatments for nosocomial pneumonia. Antimicrob Agents Chemother. 2020;65(1):e01468-e1520.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Carmeli Y, Knechtle P, Hardenberg J, et al. A randomized phase 2 study of cefepime combined with the novel extended spectrum β-lactamase inhibitor enmetazobactam in hospitalized adults with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) [abstract no 1479]. OFID. 2019;6(Suppl 2):S539.

    Article  PubMed Central  Google Scholar 

Download references

Funding

The preparation of this review was not supported by any external funding.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Susan J. Keam

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Ethics declarations

Authorship and Conflict of Interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethical approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 191 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keam, S.J. Cefepime/Enmetazobactam: First Approval. Drugs (2024). https://doi.org/10.1007/s40265-024-02035-2

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40265-024-02035-2

Search

Navigation